Syntara the science explained, page-51

Is Syntara the Global leader in lysl oxidase chemistry and what does that mean ?

https://syntaratx.com.au/pipeline/

https://www.listcorp.com/asx/snt/syntara-limited/news/investor-presentation-3050238.html



So let's assume they are world leaders.


They focus on inhibiting oxidase enzymes, particularly lysyl oxidases, which are responsible for developing fibrosis by cross-linking collagen and elastin.

Syntara has developed multiple drug candidates targeting lysyl oxidases for various indications, including myelofibrosis, myelodysplastic syndrome, skin fibrosis, and organ fibrosis.

They have created both oral and topical pan-LOX inhibitors, allowing for versatile treatment approaches in different conditions.



Their lead compound, SNT-5505, has shown promising results in reducing bone marrow fibrosis in myelofibrosis patients.


Syntara's patents for their lysyl oxidase inhibitors have priority dates providing extended intellectual property protection.


Their approach has been validated through high-impact publications in prestigious journals like Nature, demonstrating the scientific rigor behind their work.


So what is the difference between other competitors inhibitors and Syntara's PAN-LOX inhibitors?

Their compounds, like SNT-5505, are pan-lysyl oxidase inhibitors, targeting the entire family of lysyl oxidase enzymes responsible for collagen and elastin cross-linking.

SNT-5505 is orally bioavailable, making it convenient for patients to take. In a Phase 2 study, SNT-5505 demonstrated a reduction in bone marrow fibrosis grade in 60% of evaluable myelofibrosis patients over 6 months.


Syntara has developed both oral and topical pan-LOX inhibitors, allowing for diverse applications in different conditions. The inhibitors have shown excellent clinical safety and tolerability.

Their mode of action complements current standard treatments, potentially enhancing overall efficacy.


Skin fibrosis

These inhibitors show promise in various indications, including myelofibrosis, myelodysplastic syndrome, skin fibrosis, and solid tumors.

These factors collectively position Syntara's pan-lysyl oxidase inhibitors as unique and potentially groundbreaking therapeutic agents in the field of fibrosis and related disorders.

Syntara's approach to lysyl oxidase chemistry is unique in several ways:They focus on inhibiting oxidase enzymes, particularly lysyl oxidases, which are responsible for developing fibrosis by cross-linking collagen and elastin.




Syntara has developed multiple drug candidates targeting lysyl oxidases for various indications, including myelofibrosis, myelodysplastic syndrome, skin fibrosis, and organ fibrosis.

They have created both oral and topical pan-LOX inhibitors, allowing for versatile treatment approaches in different conditions.Their lead compound, SNT-5505, has shown promising results in reducing bone marrow fibrosis in myelofibrosis patients.


What sets Syntara's pan-lysyl oxidase inhibitors apart from other inhibitorsTheir compounds, like SNT-5505, are pan-lysyl oxidase inhibitors, targeting the entire family of lysyl oxidase enzymes responsible for collagen and elastin cross-linking thus a comprehensive inhibition. SNT-5505 is orally bioavailable, making it convenient for patients to take.


In a Phase 2 study, SNT-5505 demonstrated a reduction in bone marrow fibrosis grade in 60% of evaluable myelofibrosis patients over 6 months.

Syntara has developed both oral and topical pan-LOX inhibitors, allowing for diverse applications in different conditions.The inhibitors have shown excellent clinical safety and tolerability.

Their mode of action complements current standard treatments, potentially enhancing overall efficacy.These inhibitors show promise in various indications, including myelofibrosis, myelodysplastic syndrome, skin fibrosis, and solid tumors.


The efficacy of Syntara's pan-LOX inhibitors has been validated through high-impact publications in prestigious journals like Nature.These factors collectively position Syntara's pan-lysyl oxidase inhibitors as unique and potentially groundbreaking therapeutic agents in the field of fibrosis and related disorders.




SNT-5505 shows promise as a treatment for myelofibrosis for several key reasons:

Novel mechanism of action: As a pan-lysyl oxidase (LOX) inhibitor, SNT-5505 targets the enzymes responsible for collagen and elastin cross-linking, potentially reducing bone marrow fibrosis


Early trial results show improvements in bone marrow fibrosis, symptom scores, and hematological parameters in some patients.Safety profile: SNT-5505 has been well-tolerated with no serious treatment-related adverse events reported.


Its safety profile makes it a good candidate for combination with JAK inhibitors, the current standard of care.The drug can be administered orally, which is convenient for patients.SNT-5505 may offer a treatment option for patients who are intolerant, unresponsive, or ineligible for current therapies.


Potential disease-modifying effects: By targeting fibrosis directly, SNT-5505 may offer benefits beyond symptom management.Early phase trials have shown promising results in reducing bone marrow fibrosis and improving blood counts.





These factors collectively make SNT-5505 a promising candidate for further investigation in myelofibrosis treatments.Some patients treated with SNT-5505 have shown stable or improved blood counts, including in cases of severe thrombocytopenia.


Early data indicates PXS-5505 may reduce collagen fibrosis in bone marrow, a unique benefit not seen with other treatments.

World class action, world class treatment.

Comments please.


References: https://ashpublications.org/blood/article/142/Supplement%201/625/502732/PXS5505-MF-101-A-Phase-1-2a-Study-to-Evaluate

https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00665


Kpax